πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9574004

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9556277

Method of treating a TL1A-associated disease or disorder with human antibodies to TL1A

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9554563

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9550837

Therapeutic uses of anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9546218

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9545451

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9540449

Anti-PCSK9 antibodies with pH-dependent binding characteristics

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9533039

Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9532555

Humanized dipeptidyl peptidase IV (DPP4) animals

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9522185

Human antibodies to GFR Ξ±3 and methods of treating pain associated with osteoarthritis or

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9511140

Stable VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9497945

Humanized dipeptidyl peptidase IV (DPP4) animals

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9498529

Methods for treating or preventing influenza virus infection by administering a serine pro

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475875

Anti-EGFRvIII antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475869

Human antibodies to fel d1 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9462794

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9453072

Anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9447173

Human antibodies to respiratory syncytial virus F protein and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9416167

Stable liquid formulations of dimer VEGF antagonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9409990

Methods of inhibiting tumor growth by antagonizing IL-6 receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9402898

Stabilized formulations containing anti-Ang2 antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9399674

Human antibodies to Clostridium difficile toxins

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9371383

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 21 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9358287

Method of treating stress hyperglycemia with human antibodies to the glucagon receptor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted